1.
Full Text
CXCL13 is the major determinant for B cell recruitment to the CSF during neuroinflammation
Journal of Neuroinflammation, ISSN 1742-2094, 05/2012, Volume 9, Issue 1, pp. 93 - 93
Background: The chemokines and cytokines CXCL13, CXCL12, CCL19, CCL21, BAFF and APRIL are believed to play a role in the recruitment of B cells to the central...
B cells and plasmablasts | BAFF | CXCL12 | CCL21 | CCL19 | CXCL13 | APRIL | MULTIPLE-SCLEROSIS LESIONS | IMMUNOLOGY | CEREBROSPINAL-FLUID | ASTROCYTES | NEUROSCIENCES | LYME NEUROBORRELIOSIS | CENTRAL-NERVOUS-SYSTEM | LIGAND | CHEMOKINE CXCL13 | RECEPTORS | EXPRESSION | B-Lymphocyte Subsets - physiology | B-Lymphocyte Subsets - pathology | Humans | Middle Aged | Male | Nervous System Diseases - diagnosis | Cell Movement - physiology | Young Adult | Inflammation Mediators - cerebrospinal fluid | B-Lymphocyte Subsets - metabolism | Chemokine CXCL13 - biosynthesis | Adolescent | Inflammation Mediators - metabolism | Nervous System Diseases - cerebrospinal fluid | Adult | Female | Aged | Chemokine CXCL13 - cerebrospinal fluid | Cohort Studies | Nervous System Diseases - pathology | Nervous system diseases | Multiple sclerosis | Immune response | Cytokines | Immunoglobulin G | Albumin | Central nervous system diseases | B cells | Immunoglobulin A | Enzyme-linked immunosorbent assay | Chemokines | Flow cytometry | Disease | Manuscripts | Recruitment | Proteins | Studies | Lymphocytes | Herpes viruses | Ligands | Immune system
B cells and plasmablasts | BAFF | CXCL12 | CCL21 | CCL19 | CXCL13 | APRIL | MULTIPLE-SCLEROSIS LESIONS | IMMUNOLOGY | CEREBROSPINAL-FLUID | ASTROCYTES | NEUROSCIENCES | LYME NEUROBORRELIOSIS | CENTRAL-NERVOUS-SYSTEM | LIGAND | CHEMOKINE CXCL13 | RECEPTORS | EXPRESSION | B-Lymphocyte Subsets - physiology | B-Lymphocyte Subsets - pathology | Humans | Middle Aged | Male | Nervous System Diseases - diagnosis | Cell Movement - physiology | Young Adult | Inflammation Mediators - cerebrospinal fluid | B-Lymphocyte Subsets - metabolism | Chemokine CXCL13 - biosynthesis | Adolescent | Inflammation Mediators - metabolism | Nervous System Diseases - cerebrospinal fluid | Adult | Female | Aged | Chemokine CXCL13 - cerebrospinal fluid | Cohort Studies | Nervous System Diseases - pathology | Nervous system diseases | Multiple sclerosis | Immune response | Cytokines | Immunoglobulin G | Albumin | Central nervous system diseases | B cells | Immunoglobulin A | Enzyme-linked immunosorbent assay | Chemokines | Flow cytometry | Disease | Manuscripts | Recruitment | Proteins | Studies | Lymphocytes | Herpes viruses | Ligands | Immune system
Journal Article
Annals of Neurology, ISSN 0364-5134, 12/2009, Volume 66, Issue 6, pp. 833 - 842
Objective Myelin oligodendrocyte glycoprotein (MOG) is a candidate target antigen in demyelinating diseases of the central nervous system (CNS). Although MOG...
AUTOANTIBODIES | MULTIPLE-SCLEROSIS | AUTOIMMUNITY | ROLES | ACUTE DISSEMINATED ENCEPHALOMYELITIS | T-CELL | DIAGNOSTIC-CRITERIA | BASIC-PROTEIN | IDENTIFICATION | NEUROSCIENCES | ANTIMYELIN ANTIBODIES | CLINICAL NEUROLOGY | Central Nervous System - metabolism | Follow-Up Studies | Immunoglobulin G - blood | Humans | Central Nervous System - pathology | Child, Preschool | Myelin-Oligodendrocyte Glycoprotein | Infant | Male | Killer Cells, Natural - pathology | Encephalomyelitis, Acute Disseminated - blood | Central Nervous System - immunology | Nerve Tissue Proteins - metabolism | Myelin-Associated Glycoprotein - immunology | Encephalomyelitis, Acute Disseminated - immunology | Immunoglobulin G - cerebrospinal fluid | Myelin Proteins | Killer Cells, Natural - metabolism | Child
AUTOANTIBODIES | MULTIPLE-SCLEROSIS | AUTOIMMUNITY | ROLES | ACUTE DISSEMINATED ENCEPHALOMYELITIS | T-CELL | DIAGNOSTIC-CRITERIA | BASIC-PROTEIN | IDENTIFICATION | NEUROSCIENCES | ANTIMYELIN ANTIBODIES | CLINICAL NEUROLOGY | Central Nervous System - metabolism | Follow-Up Studies | Immunoglobulin G - blood | Humans | Central Nervous System - pathology | Child, Preschool | Myelin-Oligodendrocyte Glycoprotein | Infant | Male | Killer Cells, Natural - pathology | Encephalomyelitis, Acute Disseminated - blood | Central Nervous System - immunology | Nerve Tissue Proteins - metabolism | Myelin-Associated Glycoprotein - immunology | Encephalomyelitis, Acute Disseminated - immunology | Immunoglobulin G - cerebrospinal fluid | Myelin Proteins | Killer Cells, Natural - metabolism | Child
Journal Article
Nature Genetics, ISSN 1061-4036, 2013, Volume 45, Issue 11, pp. 1353 - 1362
Using the ImmunoChip custom genotyping array, we analyzed 14,498 subjects with multiple sclerosis and 24,091 healthy controls for 161,311 autosomal variants...
AUTOIMMUNE | ALLELES | METAANALYSIS | GENOTYPE IMPUTATION | GENETIC RISK | INFORMATION | ANNOTATION | PRIMARY BILIARY-CIRRHOSIS | DISEASE | GENETICS & HEREDITY | GENOME-WIDE ASSOCIATION | Genetic Variation | European Continental Ancestry Group - genetics | Genetic Predisposition to Disease | Genome-Wide Association Study | Gene Frequency | Humans | Multiple Sclerosis - immunology | Genotype | Multiple Sclerosis - genetics | Chromosome Mapping | Polymorphism, Single Nucleotide | Genetic Loci | Multiple sclerosis | Chromosome mapping | Genetic susceptibility | Genetic variation | Genetic aspects | Identification and classification | Methods | Testing | Confidence intervals | Disease | Quality control | Genomes | Stratigraphy | Autoimmune diseases | Gene expression | Meta-analysis | Teknik och teknologier | TEKNIKVETENSKAP | Engineering and Technology | TECHNOLOGY
AUTOIMMUNE | ALLELES | METAANALYSIS | GENOTYPE IMPUTATION | GENETIC RISK | INFORMATION | ANNOTATION | PRIMARY BILIARY-CIRRHOSIS | DISEASE | GENETICS & HEREDITY | GENOME-WIDE ASSOCIATION | Genetic Variation | European Continental Ancestry Group - genetics | Genetic Predisposition to Disease | Genome-Wide Association Study | Gene Frequency | Humans | Multiple Sclerosis - immunology | Genotype | Multiple Sclerosis - genetics | Chromosome Mapping | Polymorphism, Single Nucleotide | Genetic Loci | Multiple sclerosis | Chromosome mapping | Genetic susceptibility | Genetic variation | Genetic aspects | Identification and classification | Methods | Testing | Confidence intervals | Disease | Quality control | Genomes | Stratigraphy | Autoimmune diseases | Gene expression | Meta-analysis | Teknik och teknologier | TEKNIKVETENSKAP | Engineering and Technology | TECHNOLOGY
Journal Article
PLoS ONE, ISSN 1932-6203, 02/2017, Volume 12, Issue 2, p. e0170395
Antibodies against biopharmaceuticals (anti-drug antibodies, ADA) have been a well-integrated part of the clinical care of multiple sclerosis (MS) in several...
REPORTER-GENE | IFN-BETA | MULTICENTER | NEUTRALIZING ANTIBODIES | THERAPY | ADALIMUMAB | MS-PATIENTS | MULTIDISCIPLINARY SCIENCES | VALIDATION | PREVALENCE | DISEASE PROGRESSION | Interferon-beta - immunology | Age Factors | Humans | Middle Aged | Natalizumab - adverse effects | Natalizumab - immunology | Child, Preschool | Infant | Male | Interferon-beta - therapeutic use | Young Adult | Time Factors | Interferon-beta - adverse effects | Natalizumab - therapeutic use | Aged, 80 and over | Antibodies - immunology | Adult | Female | Retrospective Studies | Child | Infant, Newborn | Europe | Immunologic Factors - immunology | Adolescent | Sex Factors | Multiple Sclerosis - immunology | Aged | Immunologic Factors - adverse effects | Immunologic Factors - therapeutic use | Multiple Sclerosis - drug therapy | Viral antibodies | Pharmaceutical research | Multiple sclerosis | Antibodies | Forecasts and trends | Drug discovery | Drug therapy | Testing | Drugs | Neurosciences | Data points | Immunoglobulins | Laboratories | Risk reduction | Medical screening | Patients | Biological activity | Consortia | Neurology | Hospitals | Immunogenicity | Rheumatoid arthritis | Interferon | Clinical medicine | Cost analysis | Monitoring | Mathematics | Naturvetenskap | Natural Sciences | Matematik
REPORTER-GENE | IFN-BETA | MULTICENTER | NEUTRALIZING ANTIBODIES | THERAPY | ADALIMUMAB | MS-PATIENTS | MULTIDISCIPLINARY SCIENCES | VALIDATION | PREVALENCE | DISEASE PROGRESSION | Interferon-beta - immunology | Age Factors | Humans | Middle Aged | Natalizumab - adverse effects | Natalizumab - immunology | Child, Preschool | Infant | Male | Interferon-beta - therapeutic use | Young Adult | Time Factors | Interferon-beta - adverse effects | Natalizumab - therapeutic use | Aged, 80 and over | Antibodies - immunology | Adult | Female | Retrospective Studies | Child | Infant, Newborn | Europe | Immunologic Factors - immunology | Adolescent | Sex Factors | Multiple Sclerosis - immunology | Aged | Immunologic Factors - adverse effects | Immunologic Factors - therapeutic use | Multiple Sclerosis - drug therapy | Viral antibodies | Pharmaceutical research | Multiple sclerosis | Antibodies | Forecasts and trends | Drug discovery | Drug therapy | Testing | Drugs | Neurosciences | Data points | Immunoglobulins | Laboratories | Risk reduction | Medical screening | Patients | Biological activity | Consortia | Neurology | Hospitals | Immunogenicity | Rheumatoid arthritis | Interferon | Clinical medicine | Cost analysis | Monitoring | Mathematics | Naturvetenskap | Natural Sciences | Matematik
Journal Article
Proceedings of the National Academy of Sciences of the United States of America, ISSN 0027-8424, 12/2006, Volume 103, Issue 50, pp. 19057 - 19062
Multiple sclerosis (MS) is a chronic inflammatory disease of the central nervous system. Although the cause of MS is still uncertain, many findings point...
Cytometry | Demyelinating diseases | Myelin | Humans | Cell lines | Antibodies | Oligodendroglia | Epitopes | Autoimmune diseases | Antibody formation | Axonal damage | Demyelination | Lentiviral expression | EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS | ALLERGIC ENCEPHALOMYELITIS | MULTIDISCIPLINARY SCIENCES | axonal damage | PERIPHERAL-BLOOD | CEREBROSPINAL-FLUID | ANTIMYELIN ANTIBODIES | demyelination | antibodies | CENTRAL-NERVOUS-SYSTEM | BASIC-PROTEIN | lentiviral expression | DEMYELINATING EVENT | LEWIS RAT | T-CELLS | Recombinant Proteins - metabolism | Autoantibodies - blood | Myelin-Associated Glycoprotein - genetics | Myelin-Associated Glycoprotein - metabolism | Myelin-Oligodendrocyte Glycoprotein | Rats | Multiple Sclerosis - genetics | Recombinant Proteins - genetics | Glioma - metabolism | Myelin Sheath - metabolism | Glioma - genetics | Autoantibodies - immunology | Myelin-Associated Glycoprotein - immunology | Animals | Multiple Sclerosis - immunology | Multiple Sclerosis - pathology | Myelin Proteins | Multiple Sclerosis - metabolism | Multiple sclerosis | Myelin proteins | Research | Biological Sciences
Cytometry | Demyelinating diseases | Myelin | Humans | Cell lines | Antibodies | Oligodendroglia | Epitopes | Autoimmune diseases | Antibody formation | Axonal damage | Demyelination | Lentiviral expression | EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS | ALLERGIC ENCEPHALOMYELITIS | MULTIDISCIPLINARY SCIENCES | axonal damage | PERIPHERAL-BLOOD | CEREBROSPINAL-FLUID | ANTIMYELIN ANTIBODIES | demyelination | antibodies | CENTRAL-NERVOUS-SYSTEM | BASIC-PROTEIN | lentiviral expression | DEMYELINATING EVENT | LEWIS RAT | T-CELLS | Recombinant Proteins - metabolism | Autoantibodies - blood | Myelin-Associated Glycoprotein - genetics | Myelin-Associated Glycoprotein - metabolism | Myelin-Oligodendrocyte Glycoprotein | Rats | Multiple Sclerosis - genetics | Recombinant Proteins - genetics | Glioma - metabolism | Myelin Sheath - metabolism | Glioma - genetics | Autoantibodies - immunology | Myelin-Associated Glycoprotein - immunology | Animals | Multiple Sclerosis - immunology | Multiple Sclerosis - pathology | Myelin Proteins | Multiple Sclerosis - metabolism | Multiple sclerosis | Myelin proteins | Research | Biological Sciences
Journal Article
Neurology, ISSN 0028-3878, 02/2014, Volume 82, Issue 6, pp. 470 - 473
OBJECTIVE:A serum antibody against the inward rectifying potassium channel KIR4.1 (KIR4.1-IgG) was recently discovered, which is found in almost half of adult...
PEDIATRIC MULTIPLE-SCLEROSIS | MOG | KIR4.1 | CLINICAL NEUROLOGY | Myelin-Oligodendrocyte Glycoprotein - immunology | Enzyme-Linked Immunosorbent Assay | Humans | Autoimmune Diseases - immunology | Child, Preschool | Infant | Male | Case-Control Studies | Autoantibodies - immunology | Immunoglobulin G - immunology | Potassium Channels, Inwardly Rectifying - immunology | Adolescent | Demyelinating Diseases - immunology | Nerve Fibers, Myelinated - immunology | Neuroglia - immunology | Multiple Sclerosis - immunology | Female | Brain - immunology | Child
PEDIATRIC MULTIPLE-SCLEROSIS | MOG | KIR4.1 | CLINICAL NEUROLOGY | Myelin-Oligodendrocyte Glycoprotein - immunology | Enzyme-Linked Immunosorbent Assay | Humans | Autoimmune Diseases - immunology | Child, Preschool | Infant | Male | Case-Control Studies | Autoantibodies - immunology | Immunoglobulin G - immunology | Potassium Channels, Inwardly Rectifying - immunology | Adolescent | Demyelinating Diseases - immunology | Nerve Fibers, Myelinated - immunology | Neuroglia - immunology | Multiple Sclerosis - immunology | Female | Brain - immunology | Child
Journal Article
JOURNAL OF NEUROINFLAMMATION, ISSN 1742-2094, 11/2019, Volume 16, Issue 1, pp. 1 - 11
Background Cytokines play multiple roles during neuro-inflammatory processes and several cytokines have been studied in the context of specific diseases. This...
Neuro-inflammation | NK cells | Cytokines | Immune cell subsets | CHEMOKINES | INTERLEUKIN-1-BETA | CNS | B cells | BACTERIAL | IMMUNOLOGY | CXCL13 | NEUROSCIENCES | Blood-brain barrier | MULTIPLE-SCLEROSIS | NEUROINFLAMMATION | CSF | PROGNOSTIC MARKER | CENTRAL-NERVOUS-SYSTEM | EXPRESSION
Neuro-inflammation | NK cells | Cytokines | Immune cell subsets | CHEMOKINES | INTERLEUKIN-1-BETA | CNS | B cells | BACTERIAL | IMMUNOLOGY | CXCL13 | NEUROSCIENCES | Blood-brain barrier | MULTIPLE-SCLEROSIS | NEUROINFLAMMATION | CSF | PROGNOSTIC MARKER | CENTRAL-NERVOUS-SYSTEM | EXPRESSION
Journal Article
Journal of Autoimmunity, ISSN 0896-8411, 03/2018, Volume 88, pp. 83 - 90
Beta-interferons are still among the most commonly used drugs to treat Multiple Sclerosis (MS). The use of beta-interferons is limited by the development of...
Multiple sclerosis | Anti-drug antibodies | Neutralizing antibodies | Antigenic epitope | T cell | Interferon beta | THERAPEUTICS | TREATMENT REGIMEN | IMMUNOLOGY | IFN-BETA | IMMUNOGENICITY | IMPACT | THERAPY
Multiple sclerosis | Anti-drug antibodies | Neutralizing antibodies | Antigenic epitope | T cell | Interferon beta | THERAPEUTICS | TREATMENT REGIMEN | IMMUNOLOGY | IFN-BETA | IMMUNOGENICITY | IMPACT | THERAPY
Journal Article
9.
Full Text
Natalizumab treatment decreases serum IgM and IgG levels in multiple sclerosis patients
Multiple Sclerosis Journal, ISSN 1352-4585, 10/2013, Volume 19, Issue 11, pp. 1454 - 1461
Background: Treatment with natalizumab, a humanized monoclonal antibody against alpha4beta1 integrin, is associated with an increase in lymphoid progenitor...
immunoglobulin G | Multiple sclerosis | immunoglobulin M | alpha4beta1 integrin | natalizumab | B cell homing | ALPHA-4-BETA-1 INTEGRIN | ACTIVATION | MARGINAL ZONE | VLA-4 | FLOW | CLINICAL NEUROLOGY | B-CELLS | ANTIBODY NATALIZUMAB | VCAM-1 | MEMORY | DIFFERENTIATION | Antibodies, Monoclonal, Humanized - adverse effects | Cross-Sectional Studies | Immunoglobulin G - blood | Multiple Sclerosis - blood | Natalizumab | Humans | Middle Aged | Male | B-Lymphocytes - drug effects | Immunoglobulin M - blood | Immunoglobulin A - blood | Adult | Female | Cohort Studies | Multiple Sclerosis - drug therapy
immunoglobulin G | Multiple sclerosis | immunoglobulin M | alpha4beta1 integrin | natalizumab | B cell homing | ALPHA-4-BETA-1 INTEGRIN | ACTIVATION | MARGINAL ZONE | VLA-4 | FLOW | CLINICAL NEUROLOGY | B-CELLS | ANTIBODY NATALIZUMAB | VCAM-1 | MEMORY | DIFFERENTIATION | Antibodies, Monoclonal, Humanized - adverse effects | Cross-Sectional Studies | Immunoglobulin G - blood | Multiple Sclerosis - blood | Natalizumab | Humans | Middle Aged | Male | B-Lymphocytes - drug effects | Immunoglobulin M - blood | Immunoglobulin A - blood | Adult | Female | Cohort Studies | Multiple Sclerosis - drug therapy
Journal Article
PLoS ONE, ISSN 1932-6203, 11/2016, Volume 11, Issue 11, p. e0162752
Immunogenicity of biopharmaceutical products in multiple sclerosis is a frequent side effect which has a multifactorial etiology. Here we study associations...
IFN-BETA | VITAMIN-D | BINDING-ANTIBODIES | CONTROLLED-TRIAL | IMMUNOGENICITY | NEUTRALIZING ANTIBODIES | THERAPY | INTERVAL-CENSORED-DATA | AUTOIMMUNITY | MULTIDISCIPLINARY SCIENCES | T-CELLS | Interferon-beta - immunology | Humans | Middle Aged | Natalizumab - adverse effects | Natalizumab - immunology | Male | Multiple Sclerosis - epidemiology | Interferon-beta - therapeutic use | Interferon-beta - adverse effects | Natalizumab - therapeutic use | Antibodies - immunology | Adult | Female | Databases, Factual | Multiple Sclerosis - mortality | Antibodies, Anti-Idiotypic - blood | Risk Factors | Proportional Hazards Models | Antibodies, Anti-Idiotypic - immunology | Europe - epidemiology | Patient Outcome Assessment | Multiple Sclerosis - complications | Antibodies - blood | Aged | Population Surveillance | Cohort Studies | Multiple Sclerosis - drug therapy | Multiple sclerosis | Care and treatment | Development and progression | Interferon | Backup software | Biological response modifiers | Biopharmaceutics | Neurosciences | Immunoglobulins | Laboratories | β-Interferon | Antibodies | Systematic review | Regression analysis | Patients | Consortia | Neurology | Side effects | Demographics | Immunology | Vitamin D | Immunogenicity | Etiology | Collaboration | Biomarkers | Pharmaceuticals | Medical and Health Sciences | Medicin och hälsovetenskap
IFN-BETA | VITAMIN-D | BINDING-ANTIBODIES | CONTROLLED-TRIAL | IMMUNOGENICITY | NEUTRALIZING ANTIBODIES | THERAPY | INTERVAL-CENSORED-DATA | AUTOIMMUNITY | MULTIDISCIPLINARY SCIENCES | T-CELLS | Interferon-beta - immunology | Humans | Middle Aged | Natalizumab - adverse effects | Natalizumab - immunology | Male | Multiple Sclerosis - epidemiology | Interferon-beta - therapeutic use | Interferon-beta - adverse effects | Natalizumab - therapeutic use | Antibodies - immunology | Adult | Female | Databases, Factual | Multiple Sclerosis - mortality | Antibodies, Anti-Idiotypic - blood | Risk Factors | Proportional Hazards Models | Antibodies, Anti-Idiotypic - immunology | Europe - epidemiology | Patient Outcome Assessment | Multiple Sclerosis - complications | Antibodies - blood | Aged | Population Surveillance | Cohort Studies | Multiple Sclerosis - drug therapy | Multiple sclerosis | Care and treatment | Development and progression | Interferon | Backup software | Biological response modifiers | Biopharmaceutics | Neurosciences | Immunoglobulins | Laboratories | β-Interferon | Antibodies | Systematic review | Regression analysis | Patients | Consortia | Neurology | Side effects | Demographics | Immunology | Vitamin D | Immunogenicity | Etiology | Collaboration | Biomarkers | Pharmaceuticals | Medical and Health Sciences | Medicin och hälsovetenskap
Journal Article
Annals of Neurology, ISSN 0364-5134, 01/2013, Volume 73, Issue 1, pp. 86 - 94
Objective: Intrathecal synthesis of immunoglobulin gamma (IgG) synthesis is frequently observed in patients with multiple sclerosis (MS). Whereas the extent of...
OLIGOCLONAL BANDS | POPULATION | NEONATAL FC-RECEPTOR | RITUXIMAB | DISEASE | CSF | GM ALLOTYPES | ENVIRONMENTAL RISK-FACTORS | CEREBROSPINAL-FLUID | NEUROSCIENCES | BRAIN | CLINICAL NEUROLOGY | Multiple Sclerosis - diagnosis | Immunoglobulin gamma-Chains - genetics | Humans | Middle Aged | Genetic Loci - genetics | Immunoglobulin gamma-Chains - cerebrospinal fluid | Male | Multiple Sclerosis - genetics | Immunoglobulin Heavy Chains - cerebrospinal fluid | Young Adult | Immunoglobulin G - genetics | Immunoglobulin G - cerebrospinal fluid | Adolescent | Polymorphism, Single Nucleotide - genetics | Adult | Female | Aged | Genetic Variation - genetics | Biomarkers - cerebrospinal fluid | Genome-Wide Association Study - methods | Immunoglobulin Heavy Chains - genetics | Multiple Sclerosis - metabolism
OLIGOCLONAL BANDS | POPULATION | NEONATAL FC-RECEPTOR | RITUXIMAB | DISEASE | CSF | GM ALLOTYPES | ENVIRONMENTAL RISK-FACTORS | CEREBROSPINAL-FLUID | NEUROSCIENCES | BRAIN | CLINICAL NEUROLOGY | Multiple Sclerosis - diagnosis | Immunoglobulin gamma-Chains - genetics | Humans | Middle Aged | Genetic Loci - genetics | Immunoglobulin gamma-Chains - cerebrospinal fluid | Male | Multiple Sclerosis - genetics | Immunoglobulin Heavy Chains - cerebrospinal fluid | Young Adult | Immunoglobulin G - genetics | Immunoglobulin G - cerebrospinal fluid | Adolescent | Polymorphism, Single Nucleotide - genetics | Adult | Female | Aged | Genetic Variation - genetics | Biomarkers - cerebrospinal fluid | Genome-Wide Association Study - methods | Immunoglobulin Heavy Chains - genetics | Multiple Sclerosis - metabolism
Journal Article